Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Norbert Riedel Sells 3,415 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Norbert Riedel sold 3,415 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director directly owned 7,024 shares in the company, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $0.44 during trading hours on Monday, hitting $190.46. 725,871 shares of the company’s stock were exchanged, compared to its average volume of 1,139,967. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $198.00. The firm has a market cap of $11.72 billion, a P/E ratio of -31.90, a P/E/G ratio of 0.38 and a beta of 0.22. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $169.64 and a two-hundred day moving average of $151.92.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.51 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Piper Sandler reiterated an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Barclays assumed coverage on Jazz Pharmaceuticals in a research report on Friday. They issued an “overweight” rating and a $224.00 price target for the company. Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, UBS Group restated a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $214.57.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $1,100,000. Essex Investment Management Co. LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth approximately $2,697,000. Wedge Capital Management L L P NC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $27,834,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth $605,000. Finally, Aberdeen Group plc acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at $8,629,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Neutral Sentiment: Barclays initiated research coverage on Jazz, which typically increases analyst visibility and can boost trading interest, though the note’s tone and price targets will determine the directional impact. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: A Zacks piece highlights Jazz’s reliance on international sales and discusses how geographic mix and overseas growth patterns affect Street forecasts and revenue durability — a reminder that FX, pricing and market access abroad could swing future revenue and estimates. Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
• Negative Sentiment: EVP Neena M. Patil sold 55,600 shares on Feb. 26 at about $191.56 (~$10.65M), cutting her stake roughly in half — a large, high-dollar insider sale that may pressure sentiment. SEC Filing – Patil Sale
• Negative Sentiment: SVP Mary Elizabeth Henderson sold 5,343 shares on Feb. 26 at about $194.49 (~$1.04M), reducing her position by ~15.7% — another insider sell that could be viewed negatively by some investors. SEC Filing – Henderson Sale
• Negative Sentiment: CAO Patricia Carr executed two small sales (1,253 shares on Feb. 26 at ~$194.11 and 1,117 shares on Feb. 27 at ~$190.91), trimming her holdings by ~10–11% in each filing — smaller dollar amounts but consistent with the broader pattern of insider selling. SEC Filing – Carr Sales

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.